Compounds > uridine monophosphate
Page last updated: 2024-08-17

uridine monophosphate and Disease Exacerbation

uridine monophosphate has been researched along with Disease Exacerbation in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S1
Broersen, LM; Fang, X; Heerschap, A; Jansen, D; Kiliaan, AJ; Veltien, A; Wiesmann, M; Zerbi, V1
Bajwa, J; Coleman, G; Hope, K; Jones, RW; Lawton, M; Marven, M; Passmore, P; Ritchie, CW1
Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E1
Blázquez, A; Gimeno-Ballester, V; Mar, J; San Miguel, R1
Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS1
Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH1
Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC1
Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD1
Leshno, M; Malnick, SD; Maor, Y; Melzer, E1
Heppt, F; Sticherling, M1

Reviews

1 review(s) available for uridine monophosphate and Disease Exacerbation

ArticleYear
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9

    Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014

Trials

1 trial(s) available for uridine monophosphate and Disease Exacerbation

ArticleYear
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Gastroenterology, 2015, Volume: 149, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate

2015

Other Studies

9 other study(ies) available for uridine monophosphate and Disease Exacerbation

ArticleYear
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11

    Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine

2019
Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease.
    Neurobiology of aging, 2014, Volume: 35, Issue:3

    Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Body Water; Brain; Cerebrovascular Circulation; Diffusion Tensor Imaging; Disease Models, Animal; Disease Progression; Fatty Acids, Omega-3; Male; Mice; Mice, Transgenic; Neuroprotective Agents; Presenilin-1; Uridine Monophosphate

2014
Souvenaid®: a new approach to management of early Alzheimer's disease.
    The journal of nutrition, health & aging, 2014, Volume: 18, Issue:3

    Topics: Alzheimer Disease; Choline; Cholinesterase Inhibitors; Disease Progression; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; European Union; Female; Humans; Male; Memantine; Memory, Episodic; Prodromal Symptoms; Randomized Controlled Trials as Topic; Synapses; Uridine Monophosphate

2014
Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.
    Gut, 2015, Volume: 64, Issue:8

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Health Care Costs; Hepatitis C, Chronic; Humans; Markov Chains; Middle Aged; Sofosbuvir; Spain; Uridine Monophosphate

2015
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Global public health, 2015, Volume: 10, Issue:3

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine

2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
    Annals of internal medicine, 2015, May-05, Volume: 162, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate

2015
Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Decision Support Techniques; Disease Progression; Female; Fluorenes; Hepatitis C, Chronic; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate

2016
Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir.
    Acta dermato-venereologica, 2017, 04-06, Volume: 97, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Dermatologic Agents; Disease Progression; Fluorenes; Hepatitis C; Humans; Male; Psoriasis; Risk Factors; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Ultraviolet Therapy; Uridine Monophosphate

2017